Bibliografia
BIBLIOGRAFIA
Medroxyprogesterone Acetate Decreases Th1, Th17, and Increases Th22 Responses via AHR Signaling Which Could Affect Susceptibility to Infections and Inflammatory Disease., Front Immunol. 2019 Apr
Vasomotor symptoms in menopause: a biomarker of cardiovascular disease risk and other chronic diseases?Climacteric. 2017 Aug
Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence.Collaborative Group on Hormonal Factors in Breast Cancer.Lancet. 2019 Sep 28
Breast cancer and hormone-replacement therapy in the Million Women Study.Beral V; Million Women Study Collaborators.Lancet. 2003 Aug
Big data: Some statistical issues.Cox DR, Kartsonaki C, Keogh RH., Stat Probab Lett. 2018 May
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial.Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women’s Health Initiative Investigators., JAMA. 2002 Jul 17
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial.Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O’Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S; Women’s Health Initiative Steering Committee., JAMA. 2004 Apr
Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study., Fournier A, Berrino F, Clavel-Chapelon F., Breast Cancer Res Treat. 2008 Jan;107(1):103-11. Epub 2007 Feb 27. Erratum in: Breast Cancer Res Treat. 2008 Jan
Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects.Stanczyk FZ, Hapgood JP, Winer S, Mishell DR Jr., Endocr Rev. 2013 Apr
Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women.Salpeter SR, Cheng J, Thabane L, Buckley NS, Salpeter EE., Am J Med. 2009 Nov
Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women’s Health Initiative Randomized Trials. Manson JE, Aragaki AK, Rossouw JE, Anderson GL,Prentice RL, LaCroix AZ, Chlebowski RT, Howard BV, Thomson CA, Margolis KL, Lewis CE, Stefanick ML, Jackson RD, Johnson KC, Martin LW, Shumaker SA, Espeland MA, Wactawski-Wende J; WHI Investigators., JAMA. 2017 Sep
The endometrial and breast safety of menopausal hormone therapy containing micronised progesterone: A short review., Aust N Z J Obstet Gynaecol. 2017 Feb
Progesterone and related progestins: potential new health benefits.Climacteric. 2013 Aug
